{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:42:35Z","timestamp":1790710955684,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIH Small-Animal Imaging Research Program (SAIRP)","award":["R24 CA83084"],"award-info":[{"award-number":["R24 CA83084"]}]},{"name":"NIH Center","award":["P30 CA08748"],"award-info":[{"award-number":["P30 CA08748"]}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["4R00 CA178205-2"],"award-info":[{"award-number":["4R00 CA178205-2"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","nucmedbio.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.nucmedbio.2016.06.004","type":"journal-article","created":{"date-parts":[[2016,6,29]],"date-time":"2016-06-29T07:54:16Z","timestamp":1467186856000},"page":"566-576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["A comparative evaluation of the chelators H 4 octapa and CHX-A\u2033-DTPA with the therapeutic radiometal 90 Y"],"prefix":"10.1016","volume":"43","author":[{"given":"Eric W.","family":"Price","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly J.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E.","family":"Carnazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean D.","family":"Carlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Zeglis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2830-5493","authenticated-orcid":false,"given":"Chris","family":"Orvig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason S.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0005","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.beem.2007.01.007","article-title":"Peptide receptor radionuclide therapy","volume":"21","author":"Forrer","year":"2007","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0010","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrc3925","article-title":"Radioimmunotherapy of human tumours","volume":"15","author":"Larson","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0015","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1021\/cr900325h","article-title":"Coordinating Radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease","volume":"110","author":"Wadas","year":"2010","journal-title":"Chem Rev"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0020","first-page":"703","article-title":"Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors","volume":"26","author":"Forrer","year":"2006","journal-title":"Anticancer Res"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2310\/7290.2010.00008","article-title":"Unconventional nuclides for radiopharmaceuticals","volume":"9","author":"Holland","year":"2010","journal-title":"Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0030","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00259-011-1771-7","article-title":"Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?","volume":"38","author":"Walrand","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0035","first-page":"92S","article-title":"Practical dosimetry of peptide receptor radionuclide therapy with 90Y-labeled Somatostatin analogs","volume":"46","author":"Pauwels","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0040","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2174\/157340611796799249","article-title":"(86)Y based PET radiopharmaceuticals: radiochemistry and biological applications","volume":"7","author":"Nayak","year":"2011","journal-title":"Med Chem"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0045","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1039\/C3CS60304K","article-title":"Matching chelators to radiometals for radiopharmaceuticals","volume":"43","author":"Price","year":"2014","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0050","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.114.149062","article-title":"Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates","author":"Banerjee","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0055","doi-asserted-by":"crossref","first-page":"7419","DOI":"10.1088\/0031-9155\/59\/23\/7419","article-title":"Positron range in PET imaging: non-conventional isotopes","volume":"59","author":"J\u00f8dal","year":"2014","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0060","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s00259-011-1768-2","article-title":"Quantitative imaging of 124I and 86Y with PET","volume":"38","author":"Lubberink","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0065","doi-asserted-by":"crossref","first-page":"e18198","DOI":"10.1371\/journal.pone.0018198","article-title":"HER1-targeted 86Y-Panitumumab possesses superior targeting characteristics than 86Y-Cetuximab for PET imaging of human malignant mesothelioma tumors xenografts","volume":"6","author":"Nayak","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0070","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/ijc.25409","article-title":"PET imaging of tumor angiogenesis in mice with VEGF-A\u2013targeted 86Y-CHX-A\u2033-DTPA-bevacizumab","volume":"128","author":"Nayak","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0075","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1007\/s00259-009-1370-z","article-title":"PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A\u2033-DTPA-cetuximab","volume":"37","author":"Nayak","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0080","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/ijc.25409","article-title":"PET imaging of tumor angiogenesis in mice with VEGF-A\u2013targeted 86Y-CHX-A\u2033-DTPA-bevacizumab","volume":"128","author":"Nayak","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0085","doi-asserted-by":"crossref","first-page":"550","DOI":"10.4161\/mabs.2.5.13054","article-title":"Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials","volume":"2","author":"Milenic","year":"2010","journal-title":"MAbs"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0090","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2967\/jnumed.108.055608","article-title":"In vivo Biodistribution, PET imaging, and tumor accumulation of 86Y- and 111In-Antimindin\/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice","volume":"50","author":"Schneider","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0095","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.nucmedbio.2009.01.007","article-title":"Melanoma imaging using 111In-, 86Y- and 68Ga-labeled CHX-A\u2033-Re(Arg11)CCMSH","volume":"36","author":"Wei","year":"2009","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0100","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1021\/jm0490282","article-title":"Imaging of melanoma using 64Cu-and 86Y-DOTA-ReCCMSH(Arg11), a cyclized peptide analogue of \u03b1-MSH","volume":"48","author":"McQuade","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0105","first-page":"1148","article-title":"Pharmacokinetics and Biodistribution of 86Y-trastuzumab for 90Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI","volume":"44","author":"Palm","year":"2003","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0110","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s002590050398","article-title":"Uptake kinetics of the somatostatin receptor ligand [86Y]DOTA-d Phe1-Tyr3-octreotide ([86Y]SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labelled analogue","volume":"26","author":"R\u00f6sch","year":"1999","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0115","series-title":"Nuclear oncology","first-page":"35","article-title":"Radiopharmaceuticals for imaging in oncology with special emphasis on positron-emitting agents","author":"Zeglis","year":"2013"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0120","doi-asserted-by":"crossref","first-page":"6168","DOI":"10.1039\/c0dt01595d","article-title":"A practical guide to the construction of radiometallated bioconjugates for positron emission tomography","volume":"40","author":"Zeglis","year":"2011","journal-title":"Dalton Trans"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0125","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1039\/c3cc41554f","article-title":"Tumour targeting with radiometals for diagnosis and therapy","volume":"49","author":"Ramogida","year":"2013","journal-title":"Chem Commun"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0130","doi-asserted-by":"crossref","first-page":"7176","DOI":"10.1039\/C4DT00239C","article-title":"Modular syntheses of H4octapa and H2dedpa, and yttrium coordination chemistry relevant to 86Y\/90Y radiopharmaceuticals","volume":"43","author":"Price","year":"2014","journal-title":"Dalton Trans"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0135","doi-asserted-by":"crossref","first-page":"10412","DOI":"10.1021\/ic501466z","article-title":"What a difference a carbon makes: H4octapa vs. H4C3octapa, ligands for In-111 and Lu-177 radiochemistry","volume":"53","author":"Price","year":"2014","journal-title":"Inorg Chem"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0140","doi-asserted-by":"crossref","first-page":"12707","DOI":"10.1021\/ja4049493","article-title":"H4octapa-trastuzumab: versatile acyclic chelate system for 111In and 177Lu imaging and therapy","volume":"135","author":"Price","year":"2013","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0145","doi-asserted-by":"crossref","first-page":"8670","DOI":"10.1021\/ja3024725","article-title":"H4octapa: an acyclic Chelator for 111In radiopharmaceuticals","volume":"134","author":"Price","year":"2012","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0150","first-page":"882","article-title":"Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies","volume":"35","author":"Camera","year":"1994","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0155","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0883-2897(91)90107-V","article-title":"The in vivo release of 90Y from cyclic and acyclic ligand\u2013antibody conjugates","volume":"18","author":"Harrison","year":"1991","journal-title":"Int J Rad Appl Instrum B"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0160","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1021\/jm0200759","article-title":"Synthesis and biological evaluation of novel macrocyclic ligands with pendent donor groups as potential yttrium chelators for radioimmunotherapy with improved complex formation kinetics","volume":"45","author":"Chong","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0165","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1021\/bc800050x","article-title":"Novel bimodal bifunctional ligands for radioimmunotherapy and targeted MRI","volume":"19","author":"Chong","year":"2008","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0170","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1021\/bc200696b","article-title":"Synthesis and preclinical evaluation of bifunctional ligands for improved chelation chemistry of 90Y and 177Lu for targeted radioimmunotherapy","volume":"23","author":"Kang","year":"2012","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0175","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.nucmedbio.2009.05.007","article-title":"Standardized methods for the production of high specific-activity zirconium-89","volume":"36","author":"Holland","year":"2009","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0180","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1021\/bc200288d","article-title":"Modular strategy for the construction of radiometalated antibodies for positron emission tomography based on inverse electron demand Diels\u2013Alder click chemistry","volume":"22","author":"Zeglis","year":"2011","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0185","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.2967\/jnumed.110.076174","article-title":"89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo","volume":"51","author":"Holland","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0190","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2967\/jnumed.113.126615","article-title":"A comparison of the imaging characteristics and microregional distribution of 4 hypoxia PET tracers","volume":"55","author":"Carlin","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2016.06.004_bb0195","doi-asserted-by":"crossref","first-page":"R44","DOI":"10.1186\/bcr2866","article-title":"Quantitative assays for the measurement of HER1\u2013HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action","volume":"13","author":"DeFazio-Eli","year":"2011","journal-title":"Breast Cancer Res"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096980511630107X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096980511630107X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T17:53:25Z","timestamp":1536602005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096980511630107X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S096980511630107X"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2016.06.004","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comparative evaluation of the chelators H4octapa and CHX-A\u2033-DTPA with the therapeutic radiometal 90Y","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2016.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}